| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(16)30107-3 |
| P698 | PubMed publication ID | 27279544 |
| P50 | author | Robert Motzer | Q42721742 |
| Frede Donskov | Q43282917 | ||
| Cora Sternberg | Q50385202 | ||
| Toni K Choueiri | Q88414622 | ||
| P2093 | author name string | Thomas E Hutson | |
| David F McDermott | |||
| Neeraj Agarwal | |||
| Bruce J Roth | |||
| Brian I Rini | |||
| Bernard Escudier | |||
| Daniel Y C Heng | |||
| Manuela Schmidinger | |||
| Christian Scheffold | |||
| Thomas Powles | |||
| Sumanta Pal | |||
| Nizar M Tannir | |||
| Colin Hessel | |||
| Hans J Hammers | |||
| Jae Lyun Lee | |||
| Katriina Peltola | |||
| Paul N Mainwaring | |||
| Dana T Aftab | |||
| Gisela Schwab | |||
| METEOR investigators | |||
| P2860 | cites work | Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma | Q38122564 |
| A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 | ||
| Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth | Q39472261 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Kidney cancer, version 3.2015. | Q41407499 | ||
| Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. | Q42231093 | ||
| Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. | Q45945576 | ||
| Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 | ||
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 | ||
| Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy | Q86570241 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy | Q34007924 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma | Q34293726 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models | Q34978329 | ||
| Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer | Q35010777 | ||
| EAU guidelines on renal cell carcinoma: 2014 update. | Q35548292 | ||
| The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study | Q35561464 | ||
| c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma | Q36551653 | ||
| Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 | ||
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies | Q37974894 | ||
| Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Q38062681 | ||
| P433 | issue | 7 | |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 917-927 | |
| P577 | publication date | 2016-06-05 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial | |
| P478 | volume | 17 |
| Q47329842 | A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance. |
| Q89647005 | A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma |
| Q38662419 | A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma |
| Q92572188 | A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors |
| Q91799952 | A comprehensive review of protein kinase inhibitors for cancer therapy |
| Q89037460 | A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer |
| Q90961220 | A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma |
| Q47861428 | A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma |
| Q46979728 | A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma |
| Q92875017 | A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma |
| Q33599860 | A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer |
| Q52568014 | A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. |
| Q90763649 | A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q92514240 | Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells |
| Q59811941 | Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports |
| Q56967348 | An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma |
| Q91694148 | Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration |
| Q95841180 | Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial |
| Q50573517 | Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016. |
| Q90428644 | Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma |
| Q39401628 | Anti-angiogenesis target therapy for advanced osteosarcoma (Review). |
| Q47243395 | Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. |
| Q47804859 | Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. |
| Q91808508 | Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review |
| Q38657787 | Axitinib in metastatic renal cell carcinoma: beyond the second-line setting |
| Q42364404 | Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. |
| Q60043873 | Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses |
| Q92541901 | Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer |
| Q89243901 | Bladder Cancer Academy 2018 Selected Summaries |
| Q92253913 | Bone Metastasis: Current State of Play |
| Q64231724 | Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma |
| Q64060174 | C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas |
| Q38919780 | Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity |
| Q36281483 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. |
| Q38746778 | Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms. |
| Q89158725 | Cabozantinib for renal cell carcinoma |
| Q57481747 | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| Q38668871 | Cabozantinib for the treatment of kidney cancer |
| Q39005403 | Cabozantinib for the treatment of renal cell carcinoma |
| Q56373211 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma |
| Q64040149 | Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study |
| Q42343421 | Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice |
| Q38795560 | Cabozantinib in genitourinary malignancies |
| Q33441170 | Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study |
| Q42257155 | Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential |
| Q54980900 | Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. |
| Q28072166 | Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience |
| Q38658285 | Cabozantinib in the treatment of hepatocellular carcinoma. |
| Q48273276 | Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation |
| Q41491779 | Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. |
| Q52650529 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. |
| Q50139906 | Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. |
| Q89338718 | Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints |
| Q39026733 | Cabozantinib: A Review in Advanced Renal Cell Carcinoma |
| Q37672483 | Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma |
| Q89520843 | Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma? |
| Q90811576 | Cancer du rein métastatique : quels critères de choix en 2e ligne ? |
| Q90289244 | Cancer symptom response as an oncology clinical trial end point |
| Q92143528 | Cardiovascular toxicities of therapy for genitourinary malignancies |
| Q90273428 | Changes in therapy and survival of metastatic renal cell carcinoma in Estonia |
| Q42172414 | Characterizing the outcomes of metastatic papillary renal cell carcinoma |
| Q38955815 | Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma |
| Q39115198 | Checkpoint inhibition: new treatment options in urologic cancer |
| Q38979283 | Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib |
| Q91952954 | Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma |
| Q28074834 | Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection |
| Q39442851 | Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. |
| Q47103399 | Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q58111735 | Contemporary treatment of metastatic renal cell carcinoma |
| Q33779585 | Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications |
| Q55317776 | Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. |
| Q52661758 | Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma |
| Q38673512 | Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation |
| Q38743775 | Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. |
| Q52611170 | Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma |
| Q47177700 | Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression |
| Q90466611 | Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma |
| Q55515387 | Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation. |
| Q50876563 | Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors |
| Q51096441 | Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives |
| Q99583905 | Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study |
| Q90999199 | Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma |
| Q89907550 | Effective Treatment with Cabozantinib in an Advanced Non-Small-Cell Lung Cancer Patient Harboring a CD74-ROS1 Fusion: A Case Report |
| Q55715299 | Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. |
| Q48097821 | Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. |
| Q52652060 | Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. |
| Q89074133 | Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology |
| Q38815893 | Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma |
| Q38931269 | Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). |
| Q93104008 | Emerging therapeutic agents for genitourinary cancers |
| Q36308931 | Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma |
| Q64950042 | Essential Concepts for the Management of Metastatic Spine Disease: What the Surgeon Should Know and Practice. |
| Q47141744 | Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years |
| Q47269814 | Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis |
| Q92382571 | Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis |
| Q28079861 | Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy |
| Q38676794 | Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma |
| Q49550673 | Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. |
| Q90600541 | First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options |
| Q49887893 | Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities |
| Q33919087 | Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth |
| Q41573990 | Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. |
| Q55071881 | Hypertension in malignancy-an underappreciated problem. |
| Q38734141 | Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions |
| Q39120161 | Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go? |
| Q37725613 | Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects |
| Q92400515 | Incidence and risk of fatigue in cancer patients treated with MET inhibitors: A systematic review and meta-analysis |
| Q39360604 | Integrating Immunotherapy Into the Management of Renal Cell Carcinoma |
| Q39157476 | Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies |
| Q100425500 | Kidney Cancer: An Overview of Current Therapeutic Approaches |
| Q53779030 | Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics |
| Q39103707 | Kidney cancer, ESMO 2016. |
| Q38754614 | Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy |
| Q100457384 | Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib |
| Q52632719 | Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma |
| Q55491411 | MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. |
| Q37597858 | MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy |
| Q37702041 | MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker |
| Q90651821 | Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019 |
| Q49953442 | Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma |
| Q49573718 | Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. |
| Q54936635 | Metastasis in renal cell carcinoma: Biology and implications for therapy. |
| Q92772115 | Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management |
| Q92422466 | MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge |
| Q47550490 | Multimodal treatment of advanced renal cancer in 2017. |
| Q88757885 | NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma |
| Q52864965 | New options in treatment of advanced renal cancer |
| Q37620907 | New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy |
| Q54990172 | New treatment options for metastatic renal cell carcinoma. |
| Q90609011 | Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine |
| Q90257496 | Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| Q47144667 | Novel concepts of antiangiogenic therapies in metastatic renal cell cancer |
| Q28067777 | Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer |
| Q91347054 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma |
| Q92350780 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN |
| Q64914214 | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. |
| Q59332900 | Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma |
| Q42375254 | Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. |
| Q38906250 | Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. |
| Q39095194 | Pharmacotherapy for treating metastatic clear cell renal cell carcinoma |
| Q99350272 | Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer |
| Q41431404 | Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors |
| Q54115562 | Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma |
| Q45329617 | Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma |
| Q57297210 | Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma |
| Q37433431 | Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma |
| Q57493808 | Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis |
| Q92339684 | Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study) |
| Q47645332 | Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. |
| Q100457390 | Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance) |
| Q93349430 | RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancer |
| Q92442591 | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors |
| Q64090931 | Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium |
| Q39044249 | Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer |
| Q64103672 | Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy |
| Q58607138 | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| Q63966783 | Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein |
| Q50049497 | Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma |
| Q64074600 | Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective |
| Q50297707 | Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies |
| Q90665021 | Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer? |
| Q89493245 | Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position |
| Q98291421 | Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs |
| Q92815283 | Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor |
| Q89393258 | Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies |
| Q38678038 | Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials |
| Q57803800 | Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
| Q92977454 | Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results |
| Q52682465 | Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review |
| Q38834749 | Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms |
| Q91765164 | Sequencing therapy for advanced renal cancer |
| Q50791794 | Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale? |
| Q57071032 | Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date |
| Q64114295 | Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts |
| Q91876755 | Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry |
| Q48317645 | Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. |
| Q47134616 | Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison |
| Q47135054 | Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality |
| Q50440802 | Synergistic Activity for Natural and Synthetic Inhibitors of Angiogenesis Induced by Murine Sarcoma L-1 and Human Kidney Cancer Cells. |
| Q64083331 | Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1 |
| Q58753938 | Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour |
| Q38653012 | Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions |
| Q57301434 | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| Q50209991 | TKI 2.0 - changes in the medical treatment of renal cell carcinoma |
| Q64074959 | Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis |
| Q39425380 | Targeted therapies for renal cell carcinoma |
| Q47611824 | Targeting HIF2 in Clear Cell Renal Cell Carcinoma |
| Q64253749 | Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" |
| Q100455154 | Targeting the HIF2-VEGF axis in renal cell carcinoma |
| Q52672314 | Targeting the PI3K pathway in cancer: are we making headway? |
| Q38668940 | Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers. |
| Q92826118 | The Changing Therapeutic Landscape of Metastatic Renal Cancer |
| Q56889715 | The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma |
| Q53153700 | The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition |
| Q38681857 | The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape |
| Q92181246 | The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases |
| Q58103455 | The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study |
| Q39096266 | The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges |
| Q52645823 | The role of tumor microenvironment in resistance to anti-angiogenic therapy. |
| Q93094713 | The tumor microenvironment in renal cell cancer |
| Q92372105 | Therapeutic Sequencing in Metastatic Renal Cell Carcinoma |
| Q90230633 | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges |
| Q91994863 | Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma |
| Q64962223 | Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. |
| Q91765160 | Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study |
| Q90811595 | Traitement des métastases osseuses du cancer du rein |
| Q47726014 | Treatment of renal cell carcinoma: Current status and future directions |
| Q39092934 | Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors |
| Q41660750 | Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. |
| Q92675371 | Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma |
| Q90160018 | Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma |
| Q49394586 | What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality? |
| Q104517656 | [French ccAFU guidelines - update 2020-2022: management of kidney cancer] |
| Q57787332 | mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience |
| Q64095786 | mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model |
Search more.